NicOx SA
1900 Route des Crêtes, BP 313
Sophia-Antipolis
Cedex
06906
France
Tel: 33-0-4-92387020
Fax: 33-0-4-92387030
Website: http://www.nicox.com/
290 articles about NicOx SA
-
This is the latest rundown of people coming and going from executive positions at biopharma companies that BioSpace covers. This regular column highlights the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits.
-
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024
3/13/2024
Nicox SA, an international ophthalmology company, provided an update on its corporate and development strategy, in the context of its debt restructuring and the appointment of Gavin Spencer as Chief Executive Officer and announced it will be holding a Webcast on March 18, 2024 at 6:00 pm CET.
-
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting
3/5/2024
Nicox SA, an international ophthalmology company, provided details of poster presentations highlighting data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting, one of the key scientific events in vision research, which was held on February 29th to March 3rd, 2024 in Huntington Beach, CA, United States.
-
Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial
2/28/2024
Nicox SA, an international ophthalmology company, announced that it has signed an agreement in principle to amend its debt agreements with funds and accounts managed by BlackRock, Inc. and its affiliates.
-
Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO
2/28/2024
Nicox SA, an international ophthalmology company, announced its Board of Directors has appointed the highly experienced biotech executive Gavin Spencer as Chief Executive Officer.
-
Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan
2/8/2024
Nicox SA announced the signature of an agreement granting Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-breaking research, development and marketing, exclusive Japanese rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop, for the lowering of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
-
Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
2/6/2024
Nicox SA announced presentations on NCX 470 and NCX 1728 at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024, a key ophthalmology conference which will be held from May 5 to May 9, 2024 in Seattle, WA, United States.
-
Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA®
1/31/2024
Nicox SA announced that the United States Patent and Trademark Office (USPTO) has determined that U.S. Patent No. 7,629,345, which covers latanoprostene bunod, commercialized by Bausch + Lomb under the trademark VYZULTA®, is eligible for patent term extension of five years.
-
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
1/25/2024
Nicox SA provided financial and business highlights for the fourth quarter of 2023 for Nicox SA and its subsidiaries.
-
Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma
12/18/2023
Sophia Antipolis, France Nicox SA, an international ophthalmology company, announced that the first patient has been screened in the Whistler Phase 3b clinical trial investigating the dual mechanism of action of NCX 470 in intraocular pressure lowering.
-
Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan
12/14/2023
Nicox SA, an international ophthalmology company, announced that new nonclinical data on NCX 470 demonstrating greater intraocular pressure lowering than Lumigan® upon both single and repeated dosing in an in vivo nonclinical model has been published in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics.
-
Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones
10/20/2023
Nicox SA provided financial results for Nicox SA and its subsidiaries for the first half of 2023 and for the third quarter of 2023 and provided an update on key future milestones.
-
Nicox Provides Second Quarter 2023 Financial and Business Highlights
7/19/2023
Nicox SA provided financial and business highlights for the second quarter 2023 for Nicox SA and its subsidiaries.
-
Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million
7/10/2023
Nicox SA provided details of a U.S. market survey evaluating the commercial potential of NCX 470, a nitric oxide -donating bimatoprost, in development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension and estimated potential global annual net sales for NCX 470.
-
Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress
7/3/2023
Nicox SA announced that additional data on NCX 470 have been presented at the 10th World Glaucoma Congress (WGC) being held from June 28 to July 1, 2023 in Rome, Italy.
-
Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China
4/28/2023
Nicox SA announced that the New Drug Application for approval to commercialize ZERVIATE®, 0.24%, submitted in China by its exclusive Chinese partner, Ocumension Therapeutics, has been included in the priority review and approval process of National Medical Products Administration of the People’s Republic of China.
-
Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023
4/26/2023
Nicox SA announced that the transfer of the listing of the securities issued by the Company from the Euronext Paris regulated market to the Euronext Growth Paris multilateral trading facility, will be effective as from the trading session of April 28, 2023.
-
New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023
4/26/2023
Nicox SA announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology Annual Meeting 2023 being held April 23-27, 2023 in New Orleans, LA, United States.
-
Nicox Provides First Quarter 2023 Financial and Business Highlights
4/19/2023
Nicox SA, an international ophthalmology company, provided financial and business highlights for the first quarter 2023 for Nicox SA and its subsidiaries.
-
Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China
4/14/2023
Nicox SA, an international ophthalmology company, announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a New Drug Application for approval to commercialize ZERVIATE®, 0.24%, in China, for ocular itching associated with allergic conjunctivitis.